NEWARK, Calif., March 5, 2019 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and
year end 2018 financial results after the NASDAQ market closes on
Tuesday, March 12, 2019. Protagonist
management will host a year end update call at 4:30 p.m. EDT/1:30 p.m.
PDT the same day.
Conference Call and Webcast Information
Protagonist executives will host a conference call at
4:30 p.m. EDT/1:30 p.m. PDT on Tuesday, March 12, 2019. To
access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and
refer to conference ID number 9688334. The call will also be
webcast and will be accessible from "Events & Presentations" in
the Investors section of the company's website at
www.protagonist-inc.com. A replay will be available on the
company's website approximately two hours after the call and will
remain available for 60 days.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-300 is an injectable hepcidin mimetic for the potential
treatment of anemia and iron overload related to rare blood
diseases with an initial focus on beta thalassemia. PTG-200 is an
oral peptide interleukin-23 receptor antagonist in development for
the treatment of Crohn's disease. The company has entered into a
worldwide license and collaboration agreement with Janssen Biotech
for the clinical development of PTG-200. PN-943 is an oral,
gut-restricted alpha-4-beta-7 integrin antagonist peptide in
development for the treatment of inflammatory bowel disease.
Protagonist is headquartered in Newark, California, with pre-clinical and
clinical staff in California and
discovery operations in both California and Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-announce-fourth-quarter-and-full-year-2018-financial-results-300806515.html
SOURCE Protagonist Therapeutics, Inc.